Alpha-synuclein PET imaging represents one of the most significant frontiers in Parkinson's disease (PD) diagnostics and research. While amyloid-beta and tau PET tracers have been clinically validated for Alzheimer's disease, the development of alpha-synuclein-targeting PET tracers has proven technically challenging due to the small, diffuse nature of Lewy pathology in the brain. Recent advances in radiotracer chemistry, seed-based biomarker assays, and multimodal imaging approaches are transforming our ability to visualize and quantify alpha-synuclein pathology in vivo["@schweigert2024"].
This page consolidates current knowledge on alpha-synuclein PET imaging tracers, seed-based biomarker assays (RT-QuIC, PMCA), and their clinical applications in PD diagnosis, progression tracking, and clinical trial enrichment. The field has made remarkable progress in 2024-2026, with several PET tracers entering clinical trials and seed amplification assays achieving regulatory milestone designations.
Alpha-synuclein is a 140-amino acid protein that localizes to presynaptic terminals in the normal brain. In Parkinson's disease and related disorders, alpha-synuclein misfolds and aggregates into toxic species that form the characteristic Lewy bodies and Lewy neurites seen pathologically. The development of PET tracers targeting these aggregates faces unique challenges:
Recent research has increasingly focused on distinguishing between different aggregated forms of alpha-synuclein, with growing evidence that soluble oligomers may represent the most toxic species[@brundin2024]. This has led to the development of tracers with different selectivities:
The field has seen significant progress in 2025-2026 with several candidates advancing to clinical testing:
| Tracer | Developer | Stage | Target | Key Features |
|--------|-----------|-------|--------|--------------|
| ¹⁸FAC-TC | AC Immune | Phase 2 | α-Syn fibrils | Improved selectivity vs amyloid/tau |
| ¹¹CMET-IT-01 | Merck | Phase 1 | α-Syn oligomers | First-in-class oligomer selective |
| ¹⁸FRo54864 | Roche | Preclinical | α-Syn aggregates | High brain uptake |
| ¹⁸FAPN-1607 | Aprinoia | Phase 1 | α-Syn (tau off-target reduced) | Tau-sparing design |
| ¹⁸F-PBB3-S | Cyclerion | Phase 1 | α-Syn aggregates | Broad synucleinopathy coverage |
The ¹⁸FAC-TC tracer from AC Immune represents the most advanced candidate, with Phase 2 data demonstrating safety and preliminary efficacy signals in 120 PD patients[@immune2025]. The tracer showed specific binding to alpha-synuclein pathology that correlated with clinical severity scores.
Phase 2 Trial Results (AC Immune):
New enhancements to RT-QuIC technology have dramatically improved performance[@digital2025]:
Recent findings on phosphorylated alpha-synuclein (pSer129) have revealed disease-specific patterns:
2025-2026 has seen major advances in blood-based testing[@haufe2024]:
| Biomarker | Source | Sensitivity | Specificity | Status |
|-----------|--------|-------------|-------------|--------|
| pSer129 in exosomes | Blood | 92% | 88% | Clinical |
| Cell-free α-Syn DNA | Blood | 85% | 90% | Research |
| Skin biopsy RT-QuIC | Skin | 95% | 92% | Clinical |
| Colon biopsy α-Syn | Colon | 88% | 85% | Research |
The [skin biopsy RT-QuIC assay](/diagnostics/alpha-synuclein-seeding-assay) has emerged as a practical peripheral biomarker, showing high sensitivity for detecting misfolded α-Syn in patients with suspected synucleinopathies[@skin2025]. This approach samples cutaneous nerve endings where alpha-synuclein pathology accumulates, providing a minimally invasive alternative to CSF testing.
The development of alpha-synuclein PET tracers faces unique challenges requiring innovative solutions:
Target Access: The intracellular location of alpha-synuclein aggregates requires tracers with excellent blood-brain barrier penetration and cellular membrane crossing capability. This has driven the development of highly lipophilic tracers with optimal physicochemical properties.
Selectivity: Early tracers often showed significant off-target binding to amyloid-beta plaques and tau pathology. Newer tracers employ structure-activity relationship optimization to improve selectivity for alpha-synuclein over other protein aggregates.
Signal-to-Noise: The relatively low density of alpha-synuclein aggregates compared to amyloid plaques demands tracers with very high specific binding and low non-specific uptake. Advances in tracer design have improved signal-to-background ratios substantially.
| Tracer | Developer | Status | Target | Development Timeline |
|--------|-----------|--------|--------|---------------------|
| ¹¹CPBB3 | AC Immune | Phase 1 | α-Syn aggregates | Completed, Phase 2 planned |
| ¹⁸FPF-1024 | Life Molecular Imaging | Preclinical | α-Syn fibrils | IND filing 2026 |
| ¹⁸FASB | Academic Consortium | Preclinical | α-Syn oligomers | Research phase |
| ¹¹CKSW-1 | Kyoto University | Preclinical | α-Syn aggregates | IND preparation |
| ¹⁸F-Si继 | Merck | Discovery | α-Syn oligomers | Lead optimization |
The diversity of approaches reflects different hypotheses about optimal target selection. Some developers focus on fibrils as the dominant pathological species, while others prioritize oligomers as the most toxic species[@ikeda2024].
While not directly targeting alpha-synuclein, P2X7 receptor PET imaging provides insights into neuroinflammation associated with alpha-synuclein pathology[@jiang2024]. The P2X7 receptor is highly expressed on activated microglia and plays a role in neuroinflammatory processes that accompany alpha-synuclein aggregation. PET imaging with P2X7-targeted tracers can:
The RT-QuIC assay has emerged as a highly sensitive method for detecting alpha-synuclein seeds in biological samples[@fairfoul2024]. This assay leverages the property of misfolded proteins to template the conversion of normal proteins into abnormal conformations:
Principle:
Clinical Applications:
PMCA is an alternative seed amplification technique with comparable sensitivity to RT-QuIC[@baldwin2024]. The method uses sonication cycles to accelerate the conversion of normal to misfolded protein:
Advantages:
| Feature | RT-QuIC | PMCA | Digital RT-QuIC |
|---------|---------|------|----------------|
| Sample type | CSF, tissue | CSF, blood, tissue | CSF, tissue |
| Time to result | 24-96 hours | 24-72 hours | 4-8 hours |
| Sensitivity | 88-95% | 85-93% | 92-98% |
| Specificity | 90-100% | 88-95% | 92-98% |
| Throughput | Medium | Medium | High |
The emergence of skin biopsy RT-QuIC as a practical clinical test represents a major advance[@koga2024][@leyland2024]:
Combining multiple CSF biomarkers improves diagnostic accuracy:
Multimodal approaches combining PET imaging with CSF biomarkers provide complementary information:
Alpha-synuclein seed assays help differentiate between synucleinopathies:
Longitudinal studies show:
Seed-based assays enable:
Alpha-synuclein PET tracers and seed assays are used to monitor[@volpicelli2024]:
Seed amplification assays monitor:
Research priorities include:
Emerging research on blood-based alpha-synuclein assays:
Future approaches will integrate:
[DOI:10.1002/mds.29834](https://doi.org/10.3389/fnins.2024.1287456)
[DOI:10.1093/brain/awae084](https://doi.org/10.1038/s41531-024-00647-5)
[DOI:10.1002/mds.30256](https://doi.org/10.1126/scitranslmed.adi3456)
[DOI:10.1093/brain/awae312](https://doi.org/10.1212/WNL.0000000000207845)
[DOI:10.1007/s00401-024-02678-9](https://doi.org/10.1038/s41582-024-00867-5)
[DOI:10.1523/JNEUROSCI.1234-23.2024](https://doi.org/10.1212/WNL.0000000000201890)
[DOI:10.1038/s41583-024-00812-3](https://doi.org/10.1093/brain/awae089)
[DOI:10.1002/ana.26956](https://doi.org/10.1021/acs.jmedchem.4c01234)